海欣股份一季度净利微增，主力资金周内净流出

Core Viewpoint - The company reported a slight decline in revenue for Q1 2025, while net profit showed a modest increase, indicating mixed performance in the current financial period [1]. Financial Performance - For Q1 2025, the company's operating revenue was 202 million yuan, a year-on-year decrease of 3.02% - The net profit attributable to shareholders was 33.02 million yuan, reflecting a year-on-year increase of 2.58% [1] - The sales net profit margin stood at 18.45%, and the return on equity was 0.77% as of Q1 2025 [2]. Industry Policy and Environment - The launch of China's drug price registration system in December 2025 is expected to enhance price transparency in the pharmaceutical sector, which may have long-term implications for chemical pharmaceutical companies like Hai Xin [3]. Capital Movement - As of the week ending December 19, 2025, the company experienced a net outflow of main funds amounting to 7.3273 million yuan, with the stock price closing at 7.13 yuan, reflecting a weekly increase of 3.48% [4].